Project Grant R21CA302802
Award Date 9/4/25
Completion Date 8/31/27
Dollars Obligated $412K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the University of Oklahoma Health Sciences Center to conduct a randomized factorial trial on smoking cessation interventions. The $625,201 award, effective January 1, 2025 through December 31, 2029, will evaluate the combined impact of varenicline medication plus nicotine lozenges, and a smartphone-based medication adherence intervention, on 7-day point prevalence...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $687,995.00 to Yale University to conduct a randomized clinical trial investigating the efficacy of varenicline (Chantix) for cessation of electronic cigarette (e-cigarette) use in adults. The study aims to test the hypothesis that varenicline is an effective intervention for helping e-cigarette users quit, given the addictive nature of nicotine in e-cigarettes and...
- This Project Grant award of $320,000 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a smoking and vaping cessation treatment based on the drug candidate cytisine. The goal is to explore the feasibility of delivering cytisine through electronic vape administration (EVA) to help stabilize dopamine release and reduce nicotine self-administration in a mouse model of nicotine addiction. Key activities include...
- This $515,632 Project Grant from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to prepare the U.S. and states for potential new cigarette product standards that could significantly increase smoking cessation rates. The research team at the University of Minnesota will provide state-specific estimates of the number of people who smoke (PWS) that will quit smoking in response to a menthol ban and nicotine reduction standard, as well as the...
- This federal Project Grant award of $619,175 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports a Type 1 hybrid effectiveness-implementation trial to evaluate a novel harm reduction approach for oncology outpatients who smoke but refuse traditional tobacco treatment. The study will directly compare rates of switching from cigarettes to e-cigarettes against standard care, while also assessing key barriers and facilitators to implementation. The...
- The National Cancer Institute (NCI) awarded a $399,891 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Sensewhy, Inc. (UEI: N7FTT2U8NHX7) to evaluate the feasibility and clinical utility of the "Smokemon" wearable device for detecting smoking topography and predicting smoking lapses among cancer survivors who are daily smokers. The project will involve a one-week pre-quit observation period and a four-week post-quit observation period, during which...
- The federal Project Grant award titled "Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit" is funded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $663,554.00 with an award date of August 18, 2025 and an ultimate completion date of July 31, 2030. The grant supports research to explore the use of harm reduction product sampling, such as e-cigarettes, heated tobacco products, and oral...
- The Regents of the University of Minnesota received a $1,389,542 Project Grant from the National Institute on Minority Health and Health Disparities (CFDA 93.307 Minority Health and Health Disparities Research Program) to evaluate population-based strategies for improving smoking cessation among rural residents. The project aims to determine the efficacy of providing free nicotine replacement therapy (NRT) starter kits, along with digital NRT education, to rural smokers. Additionally, the...
- This $674,709 Project Grant awarded on July 15, 2025 by the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports research aimed at understanding the neural mechanisms underlying the effects of continuous theta burst stimulation (cTBS) on inhibitory control and craving regulation in nicotine addiction. The research, conducted by the University of Missouri System, involves a location control crossover study examining how cTBS...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research), is focused on developing a cue-based smoking cessation intervention delivered via telehealth for people who smoke lightly (PSLI). The $906,306 award, with a performance period from September 2025 to August 2028, aims to adapt and pilot test an intervention that combines cue-based treatment with standard cognitive behavioral therapy (CBT) to promote smoking cessation...